Back to top
more

SCYNEXIS, Inc. (SCYX)

(Delayed Data from NSDQ)

$1.14 USD

1.14
337,551

+0.06 (5.56%)

Updated Oct 17, 2019 04:00 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | C Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for SCYX

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

INDUSTRY: Medical - Drugs

Reports for Purchase

Showing records 141 - 160 ( 16470 total )

Company: OptiNose, Inc.

Industry: Medical - Drugs

Record: 141

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for OPTN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Pacira Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 142

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PCRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Dipexium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 143

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PLXP

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Opiant Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 144

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for OPNT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ono Pharmaceutical Co.

Industry: Medical - Drugs

Record: 145

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for OPHLF

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Onconova Therapeutics, Inc.

Industry: Medical - Drugs

Record: 146

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ONTX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Odonate Therapeutics, Inc.

Industry: Medical - Drugs

Record: 147

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ODT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ocular Therapeutix, Inc.

Industry: Medical - Drugs

Record: 148

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for OCUL

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Matinas Biopharma Holdings, Inc.

Industry: Medical - Drugs

Record: 149

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MTNB

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: RXi Pharmaceuticals Corporation

Industry: Medical - Drugs

Record: 150

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PHIO

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Molecular Templates Inc.

Industry: Medical - Drugs

Record: 151

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MTEM

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Portola Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 152

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PTLA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Tokai Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 153

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for NVUS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Majesco Entertainment Company

Industry: Medical - Drugs

Record: 154

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PTE

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: PTC Therapeutics, Inc.

Industry: Medical - Drugs

Record: 155

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PTCT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Neon Therapeutics, Inc.

Industry: Medical - Drugs

Record: 156

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for NTGN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Marinus Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 157

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MRNS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Novan Inc.

Industry: Medical - Drugs

Record: 158

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for NOVN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 159

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for RIGL

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 160

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for NBIX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party